[R01] Targeted degradation of CDK4 and 6 to overcome treatment resistance in breast cancer

Ente: National Cancer Institute

Scadenza: 2030-05-31

Importo max: $627,371

Paese: US

Descrizione

Abstract Although CDK4/6 inhibitors (in combination with an endocrine therapy) are the preferred systemic therapy for treatment of patients with metastatic, Estrogen Receptor-positive (ER+) breast cancer (BC), development of resistance to CDK4/6 inhibitors is universal. Therefore, development of nov

Settori: National Cancer Institute

Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.